CRISPR Variant Enables More Accurate Genome Editing
|
By LabMedica International staff writers Posted on 13 Aug 2018 |

Image: An illustration showing the protein cas12a bound to a DNA helix (red and white) (Photo courtesy of T. Yamano and H. Nishimasu / James Rybarski).
Results of a recent study suggested that inherent binding properties of the Cas12a enzyme make it a better choice for gene editing purposes than the currently used CRISPR/Cas9 combination.
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Despite the widespread usage of CRISPR/Cas9, DNA cleavage at off-target sites that resemble the target sequence continues to be a pervasive problem that remains poorly understood mechanistically.
To solve the problem of off-target DNA cleavage, investigators at the University of Texas at Austin (USA) used quantitative kinetics to dissect the reaction steps of DNA targeting by Cas12a (also known as Cpf1 or Centromere and Promoter Factor 1). CRISPR/Cpf1 differs from CRISPR/Cas9 in a number of key ways. Cpf1 is much smaller than the Cas9 enzyme, which makes it easier to package inside a virus and therefore easier to deliver to muscle cells. It also recognizes a different sequence of DNA than Cas9 does, which provides greater flexibility in terms of use.
The investigators reported in the August 2, 2018, online edition of the journal Molecular Cell that Cas12a bound DNA tightly in two kinetically separable steps and discriminated strongly against mismatches along most of the DNA target sequence. In mechanistic terms, the investigators explained that Cas9, initially bound base pairs tightly together, but after the first seven or eight base pairs in the genomic target it paid less attention. This implied that Cas9 could overlook mismatches that could lead it to edit the wrong part of the genome. In contrast, Cas12a formed bonds that were relatively weak. Thus, it required a good match all along the target molecule to hold the complex together long enough to make an edit. Therefore it was much more likely to edit only the intended part of the genome.
"It makes the process of base-pair formation more reversible," said senior author Dr. Rick Russell, professor of molecular biosciences at University of Texas at Austin. "In other words, Cas12a does a better job of checking each base pair before moving on to the next one. After seven or eight letters, Cas9 stops checking, whereas Cas12a keeps on checking out to about 18 letters."
Related Links:
University of Texas at Austin
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Despite the widespread usage of CRISPR/Cas9, DNA cleavage at off-target sites that resemble the target sequence continues to be a pervasive problem that remains poorly understood mechanistically.
To solve the problem of off-target DNA cleavage, investigators at the University of Texas at Austin (USA) used quantitative kinetics to dissect the reaction steps of DNA targeting by Cas12a (also known as Cpf1 or Centromere and Promoter Factor 1). CRISPR/Cpf1 differs from CRISPR/Cas9 in a number of key ways. Cpf1 is much smaller than the Cas9 enzyme, which makes it easier to package inside a virus and therefore easier to deliver to muscle cells. It also recognizes a different sequence of DNA than Cas9 does, which provides greater flexibility in terms of use.
The investigators reported in the August 2, 2018, online edition of the journal Molecular Cell that Cas12a bound DNA tightly in two kinetically separable steps and discriminated strongly against mismatches along most of the DNA target sequence. In mechanistic terms, the investigators explained that Cas9, initially bound base pairs tightly together, but after the first seven or eight base pairs in the genomic target it paid less attention. This implied that Cas9 could overlook mismatches that could lead it to edit the wrong part of the genome. In contrast, Cas12a formed bonds that were relatively weak. Thus, it required a good match all along the target molecule to hold the complex together long enough to make an edit. Therefore it was much more likely to edit only the intended part of the genome.
"It makes the process of base-pair formation more reversible," said senior author Dr. Rick Russell, professor of molecular biosciences at University of Texas at Austin. "In other words, Cas12a does a better job of checking each base pair before moving on to the next one. After seven or eight letters, Cas9 stops checking, whereas Cas12a keeps on checking out to about 18 letters."
Related Links:
University of Texas at Austin
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Novel Liquid Biopsy Technology to Advance Cancer Diagnostics
Liquid biopsies are increasingly replacing tissue biopsies in cancer care, offering a faster, minimally invasive way to assess tumor genetics from blood samples. However, current liquid biopsy methods... Read more
POC Oral Fluid Test Diagnoses HIV Infection in 20 Minutes
Timely and accurate HIV diagnosis remains a major challenge in many parts of the world, particularly in resource-constrained settings where laboratory infrastructure and trained personnel are limited.... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channel
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read morePathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more







